Our Products

DESCRIPTION:
Gel implant for restoring and maintaining soft tissue volume Highfil-Rus 2%. 

COMPOSITION:
Hyfil-Rus 2% gel implant in a 1.0 ml syringe, with 30G needles – 2 pcs

INDICATIONS:
Correction of moderate and deep facial wrinkles (such as nasolabial folds).
Changing the shape and volume of the lips.

STORAGE CONDITIONS:
The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

REGISTRATION CERTIFICATE NUMBER:
RZN 2013/99 dated March 06, 2013

DESCRIPTION:
Clear, colorless, viscoelastic liquid in a pre-filled syringe.

COMPOSITION:
Hyorth-Rus implant sterile for intra-articular injection 1% syringe 2ml Complete with G19 needle No. 1

INDICATIONS:
Hyorth-Rus is used in the treatment of pain in osteoarthritis (OA) of the knee and other joints with the ineffectiveness of traditional non-drug methods and first-line analgesics.

STORAGE CONDITIONS:
Store at a temperature not exceeding 25°C. Store in a place protected from light. Do not freeze.

REGISTRATION CERTIFICATE NUMBER:
RZN 2013/100 DATED APRIL 04, 2013

DESCRIPTION:
Antitumor agent of alkylating action, has an imidazole atrazine structure.

COMPOSITION:
Colloidal silicon dioxide 6 mg, tartaric acid 11 mg, sodium carboxymethyl starch 10 mg, anhydrous lactose 199 mg, stearic acid 4 mg. Gelatin capsule composition: titanium dioxide 1.5%, iron oxide red dye 0.8-1%, gelatin up to 100%.

INDICATIONS:
Newly diagnosed glioblastoma multiforme; malignant glioma  in the presence of recurrence or progression of the disease after standard therapy; widespread metastatic melanoma.

STORAGE CONDITIONS:
In a dry place, protected from light, at a temperature not exceeding 25 °C. Keep out of reach of children.

REGISTRATION CERTIFICATE NUMBER:
LP-002503 DATED June 16, 2014

DESCRIPTION:
Lyophilized mass or powder of white to almost white color.

COMPOSITION:
For 1 bottle of lyophilizate: Active substance – Zoledronic acid 4.0 mg (as Zoledronic acid monohydrate 4.26 mg). Auxiliary substances – Mannitol 220.0 mg; Sodium Citrate 24.0 mg

INDICATIONS:
Hypercalcemia (serum albumin-adjusted calcium concentration ≥12 mg/dl or 3 mmol/L) induced by malignant tumors. Metastatic bone damage in malignant solid tumors and myeloma (to reduce the risk of pathological fractures, spinal cord compression, tumor-related hypercalcemia, and reduce the need for radiation therapy).

STORAGE CONDITIONS:

Store in a dry place, protected from light, at a temperature of 15 to 30 °C. Keep out of reach of children.

REGISTRATION CERTIFICATE NUMBER:
LSR-008823/10 DATED AUGUST 07, 2010

DESCRIPTION:
Clear, viscous solution of yellow to brownish-yellow color.

COMPOSITION:
Active substance: docetaxel trihydrate (based on docetaxel) 20.0 mg, 80 mg, 120 mg; excipients: polysorbate-80 0.5 ml, 2 ml, 3 ml.

INDICATIONS:
Locally advanced or metastatic breast cancer as a primary chemotherapeutic treatment (1st line) or with ineffective previous therapy, with the inclusion of anthracyclines (2nd line); Locally advanced or metastatic non-small cell lung cancer with the ineffectiveness of previous therapy with the inclusion of platinum preparations; Metastatic ovarian cancer with the ineffectiveness of previous therapy with the inclusion of platinum preparations.

STORAGE CONDITIONS:
Store in a dry place, protected from light, at a temperature of 2 to 8 °C. Keep out of reach of children.

REGISTRATION CERTIFICATE NUMBER:
LSR-008696/10 from AUGUST 25, 2010